for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Crispr Therapeutics AG

CRSP.O

Latest Trade

85.90USD

Change

0.76(+0.89%)

Volume

643,356

Today's Range

83.40

 - 

87.71

52 Week Range

32.30

 - 

105.12

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
85.14
Open
85.75
Volume
643,356
3M AVG Volume
21.71
Today's High
87.71
Today's Low
83.40
52 Week High
105.12
52 Week Low
32.30
Shares Out (MIL)
70.17
Market Cap (MIL)
5,974.44
Forward P/E
-17.92
Dividend (Yield %)
--

Next Event

Q3 2020 CRISPR Therapeutics AG Earnings Release

Latest Developments

More

CRISPR Total Q2 Collaboration Revenue Was Less Than $0.1 Million

Crispr Therapeutics AG Says Public Offering Of 6.43 Million Common Shares Priced At $70.00 Per Share

Crispr Therapeutics Commencing Underwritten Public Offering Of $325 Mln Of Common Shares

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Crispr Therapeutics AG

CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases. The Company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The Company has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The Company has business operations in London and the United Kingdom, as well as research and development operations in the United States.

Industry

Biotechnology & Drugs

Contact Info

Baarerstrasse 14

ZUG, ZUG

6300

Switzerland

+41.41.5613277

http://www.crisprtx.com/about-us/contact

Executive Leadership

Rodger Novak

Chairman of the Board, President, Co-Founder

Samarth Kulkarni

Chief Executive Officer, Director

Michael John Tomsicek

Chief Financial Officer

Lawrence Otto Klein

Chief Operating Officer, Chief Business Officer

Tony W. Ho

Executive Vice President - Research and Development

Key Stats

2.25 mean rating - 16 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.3K

2020(E)

0.0K
EPS (USD)

2017

-1.710

2018

-3.440

2019

1.170

2020(E)

-4.793
Price To Earnings (TTM)
182.27
Price To Sales (TTM)
20.66
Price To Book (MRQ)
5.85
Price To Cash Flow (TTM)
224.52
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
2.73
Return on Equity (TTM)
2.54

Latest News

Latest News

BRIEF-Crispr Therapeutics AG Says Public Offering Of 6.43 Million Common Shares Priced At $70.00 Per Share

* CRISPR THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES

BRIEF-Crispr Therapeutics Commencing Underwritten Public Offering Of $325 Mln Of Common Shares

* CRISPR THERAPEUTICS AG - COMMENCING AN UNDERWRITTEN PUBLIC OFFERING OF $325 MILLION OF COMMON SHARES

BRIEF-Crispr Therapeutics And Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted To Ctx001™ For The Treatment Of Severe Hemoglobinopathies

* CRISPR THERAPEUTICS AND VERTEX PHARMACEUTICALS ANNOUNCE FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION GRANTED TO CTX001™ FOR THE TREATMENT OF SEVERE HEMOGLOBINOPATHIES Source text for Eikon: Further company coverage:

Swiss stocks - Factors to watch on April 29

The Swiss blue-chip SMI was seen opening 0.5% higher at 9,985 points on Wednesday, according to premarket indications by bank Julius Baer.

BRIEF-Crispr Therapeutics Reports First Quarter 2020 Financial Results

* CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Crispr Therapeutics Supplementing Risk Factors On Form 10-K With Potential Impacts From Coronavirus

* CRISPR THERAPEUTICS AG - SUPPLEMENTING RISK FACTORS ON FORM 10-K WITH POTENTIAL IMPACTS FROM CORONAVIRUS PANDEMIC - SEC FILING Source text: https://bit.ly/3bHHC8s Further company coverage:

BRIEF-Crispr Therapeutics Provides Business Update And Reports Fourth Quarter And Full Year 2019 Financial Results

* CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

IFR US ECM Weekly Wrap-up

WEEKLY TOTAL $9.6bn – IPO $993m – ABB/BLOCK $6.3bn – FOLLOW-ON $1.65bn – CB $705m Monday

IFR US ECM Calendar

Canaan (China, cryptocurrency) – $90m IPO. 10m ADSs (100% prim) at $9.00 versus $9-$11 marketing. CITI, CREN, CMBI. Nasdaq "CAN". 14 investors indicated an interest in 5% of the ADSs.

IFR US ECM Calendar

Canaan (China, cryptocurrency) – $90m IPO. 10m ADSs (100% prim) at $9.00 versus $9-$11 marketing. CITI, CREN, CMBI. Nasdaq "CAN". 14 investors indicated an interest in 5% of the ADSs.

IFR US ECM Calendar

Amplitude Healthcare Acquisition (US, SPAC) – $100m IPO. 10m units (100% prim) at $10.00. Each unit comprises one share and one-half of a warrant. BMO, SVBL.

IFR US ECM Calendar

Amplitude Healthcare Acquisition (US, SPAC) – $100m IPO. 10m units (100% prim) at $10.00. Each unit comprises one share and one-half of a warrant. BMO, SVBL.

GSK signs up gene-editing pioneers in drug discovery alliance

British drugmaker GSK said it has struck a research deal with the early pioneers of a prominent gene-editing technology at the University of California, in a boost to its prospects for developing new drugs.

Vertex Pharmaceuticals expands into Duchenne gene therapy with new deals

Vertex Pharmaceuticals Inc said http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20190606:nBw4wRKsa on Thursday it would acquire privately held Exonics Therapeutics for an upfront payment of $245 million and potential milestone payments...

U.S. appeals court upholds MIT, Harvard patents on CRISPR gene editing

A U.S. appeals court on Monday allowed a research center affiliated with the Massachusetts Institute of Technology and Harvard University to keep patents potentially worth billions of dollars on a groundbreaking gene editing technology known as CRISPR.

CRISPR gene editing can cause risky collateral DNA damage - study

Scientists studying the effects of the potentially game-changing gene editing tool CRISPR/Cas9 have found it can cause unexpected genetic damage which could lead to dangerous changes in some cells.

BRIEF-Crispr Therapeutics Reports Q1 Loss Per Share $0.62

* CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Crispr Therapeutics Qtrly collaboration Revenue $32.3 Mln

* CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Crispr Therapeutics Says Public Offering Of 5 Mln Common Shares Priced At $22.75/Share

* CRISPR THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES

BRIEF-Crispr Therapeutics ‍Commences Public Offering Of $100 Mln Common Shares​

* CRISPR THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up